Tag archive for ‘glembutumamab’
Celldex: Update Based on 2Q, 2016 Conference Call (CLDX, Neutral, $4.45)
Investment View Celldex has a broad array of clinical trials underway or in planning that involve five drugs. However, most of these trials are in an early exploratory stage and are designed to provide signals of activity for designing subsequent trials that could lead to approval. As such they are not likely to have much […]